Phaseline

Companies › Innate Pharma

Innate Pharma: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IPH5201
TriFaRed-Ig antibody (IgG4 Fc-silenced anti-BTLA monoclonal antibody)
–Phase 2Non Small Cell Lung CancerJun 2027
IPH4502
Nectin-4-directed antibody-drug conjugate (ADC)
NECTIN4Phase 1Advanced or Metastatic Solid TumorsApr 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05742607IPH5201Phase 2Non Small Cell Lung CancerOncologyJun 2027
NCT06781983IPH4502Phase 1Advanced or Metastatic Solid TumorsOncologyApr 2028

From the company's SEC filings

Cash and short-term investments of 34m EUR on 2025-12-31; operating cash outflow about 53m EUR a year; runway about 8 months at that burn, to Aug 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway

Targets

NECTIN4 (1)

Companies with the same targets

BicycleTx Mabwell (Shanghai) Bioscience Aktis Oncology Tianjin ConjuStar Biologics Regeneron Pharmaceuticals Astellas Samsung Bioepis Beijing Biotech Akeso Context Therapeutics

Companies built like this

Tianjin ConjuStar Biologics Radiopharm Theranostics Dogwood Therapeutics Atossa Therapeutics Curis

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.